Ibrutinib / Bortezomib / Rituximab clinical trials

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

This study is looking into a new treatment for Waldenström's Macroglobulinemia (WM), a type of blood cancer. It combines three medicines – Ibrutinib, Bortezomib, and Rituximab – to see if this chemotherapy-free approach works well and has fewer side effects in people newly diagnosed with WM.